These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 35952313)

  • 1. Evaluation of the Effectiveness of Individually Tailored Lifestyle Intervention in Patients With Familial Hypercholesterolemia.
    Beyece İncazli S; Özer S; Kayikçioğlu M
    J Cardiovasc Nurs; 2022 Sep-Oct 01; 37(5):465-474. PubMed ID: 35952313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No significant improvement of cardiovascular disease risk indicators by a lifestyle intervention in people with familial hypercholesterolemia compared to usual care: results of a randomised controlled trial.
    Broekhuizen K; van Poppel MN; Koppes LL; Kindt I; Brug J; van Mechelen W
    BMC Res Notes; 2012 Jul; 5():181. PubMed ID: 22490761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A tailored lifestyle intervention to reduce the cardiovascular disease risk of individuals with Familial Hypercholesterolemia (FH): design of the PRO-FIT randomised controlled trial.
    Broekhuizen K; van Poppel MN; Koppes LL; Brug J; van Mechelen W
    BMC Public Health; 2010 Feb; 10():69. PubMed ID: 20156339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of therapeutic lifestyle changes on lipid profiles assessed by NMR in children with familial and non-familial hypercholesterolemia.
    Rodríguez-Borjabad C; Malo AI; Ibarretxe D; Girona J; Heras M; Ferré R; Feliu A; Salvadó M; Varela A; Amigó N; Masana L; Plana N; ;
    Clin Investig Arterioscler; 2020; 32(2):49-58. PubMed ID: 32005605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is the process of delivery of an individually tailored lifestyle intervention associated with improvements in LDL cholesterol and multiple lifestyle behaviours in people with familial hypercholesterolemia?
    Broekhuizen K; Jelsma JG; van Poppel MN; Koppes LL; Brug J; van Mechelen W
    BMC Public Health; 2012 May; 12():348. PubMed ID: 22583789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An economic evaluation alongside a randomized controlled trial evaluating an individually tailored lifestyle intervention compared with usual care in people with familial hypercholesterolemia.
    Broekhuizen K; van Wier MF; Koppes LL; Brug J; van Mechelen W; Bosmans JE; van Poppel MN
    BMC Res Notes; 2015 Jul; 8():317. PubMed ID: 26219281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can multiple lifestyle behaviours be improved in people with familial hypercholesterolemia? Results of a parallel randomised controlled trial.
    Broekhuizen K; van Poppel MN; Koppes LL; Kindt I; Brug J; van Mechelen W
    PLoS One; 2012; 7(12):e50032. PubMed ID: 23251355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease knowledge and adherence to treatment in patients with familial hypercholesterolemia.
    Hollman G; Olsson AG; Ek AC
    J Cardiovasc Nurs; 2006; 21(2):103-8. PubMed ID: 16601526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patients' perceptions and experiences of familial hypercholesterolemia, cascade genetic screening and treatment.
    Hardcastle SJ; Legge E; Laundy CS; Egan SJ; French R; Watts GF; Hagger MS
    Int J Behav Med; 2015 Feb; 22(1):92-100. PubMed ID: 24585182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficiency and problems of statin therapy in patients with heterozygous familial hypercholesterolemia.
    Korneva V; Kuznetsova T; Julius U
    Atheroscler Suppl; 2019 Dec; 40():79-87. PubMed ID: 31818452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of lifestyle intervention improve cardiovascular disease risk factors in community-based menopausal transition and early postmenopausal women in China.
    Wu L; Chen R; Ma D; Zhang S; Walton-Moss B; He Z
    Menopause; 2014 Dec; 21(12):1263-8. PubMed ID: 24781851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multimodal lipid-lowering treatment in pediatric patients with homozygous familial hypercholesterolemia-target attainment requires further increase of intensity.
    Klaus G; Taylan C; Büscher R; Schmitt CP; Pape L; Oh J; Driemeyer J; Galiano M; König J; Schürfeld C; Spitthöver R; Schaefer JR; Weber LT; Heibges A; Klingel R
    Pediatr Nephrol; 2018 Jul; 33(7):1199-1208. PubMed ID: 29502162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structured advice provided by a dietitian increases adherence of consumers to diet and lifestyle changes and lowers blood low-density lipoprotein (LDL)-cholesterol: the Increasing Adherence of Consumers to Diet & Lifestyle Changes to Lower (LDL) Cholesterol (ACT) randomised controlled trial.
    Sialvera TE; Papadopoulou A; Efstathiou SP; Trautwein EA; Ras RT; Kollia N; Farajian P; Goumas G; Dimakopoulos I; Papavasiliou K; Koutsouri A; Zampelas A
    J Hum Nutr Diet; 2018 Apr; 31(2):197-208. PubMed ID: 28891084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and Safety of Lipid-Lowering Drug Treatments in Japanese Patients with Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study.
    Yamashita S; Masuda D; Harada-Shiba M; Arai H; Bujo H; Ishibashi S; Daida H; Koga N; Oikawa S
    J Atheroscler Thromb; 2022 May; 29(5):608-638. PubMed ID: 33980760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravascular ultrasound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia: the Low Density Lipoprotein-Apheresis Coronary Morphology and Reserve Trial (LACMART).
    Matsuzaki M; Hiramori K; Imaizumi T; Kitabatake A; Hishida H; Nomura M; Fujii T; Sakuma I; Fukami K; Honda T; Ogawa H; Yamagishi M
    J Am Coll Cardiol; 2002 Jul; 40(2):220-7. PubMed ID: 12106923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longitudinal low density lipoprotein cholesterol goal achievement and cardiovascular outcomes among adult patients with familial hypercholesterolemia: The CASCADE FH registry.
    Duell PB; Gidding SS; Andersen RL; Knickelbine T; Anderson L; Gianos E; Shrader P; Kindt I; O'Brien EC; McCann D; Hemphill LC; Ahmed CD; Martin SS; Larry JA; Ahmad ZS; Kullo IJ; Underberg JA; Guyton J; Thompson P; Wilemon K; Roe MT; Rader DJ; Cuchel M; Linton MF; Shapiro MD; Moriarty PM; Knowles JW
    Atherosclerosis; 2019 Oct; 289():85-93. PubMed ID: 31487564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical decision support for familial hypercholesterolemia (CDS-FH): Rationale and design of a cluster randomized trial in primary care.
    Persson Lindell O; Karlsson LO; Nilsson S; Charitakis E; Hagström E; Muhr T; Nilsson L; Henriksson M; Janzon M
    Am Heart J; 2022 May; 247():132-148. PubMed ID: 35181275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of genetic testing on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia (GenTLe-FH): a randomised waiting list controlled open-label study protocol.
    Nomura A; Tada H; Okada H; Nohara A; Ishikawa H; Yoshimura K; Kawashiri MA
    BMJ Open; 2018 Dec; 8(12):e023636. PubMed ID: 30593551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-density lipoprotein apheresis: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2007; 7(5):1-101. PubMed ID: 23074505
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.